[go: up one dir, main page]

ES2083931T1 - Combinaciones de inhibidores ace y diureticos. - Google Patents

Combinaciones de inhibidores ace y diureticos.

Info

Publication number
ES2083931T1
ES2083931T1 ES93906266T ES93906266T ES2083931T1 ES 2083931 T1 ES2083931 T1 ES 2083931T1 ES 93906266 T ES93906266 T ES 93906266T ES 93906266 T ES93906266 T ES 93906266T ES 2083931 T1 ES2083931 T1 ES 2083931T1
Authority
ES
Spain
Prior art keywords
dosage
diuretics
combinations
ace inhibitors
hypertensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES93906266T
Other languages
English (en)
Inventor
J Krister Kristianson
Per Wold-Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of ES2083931T1 publication Critical patent/ES2083931T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULACIONES FARMACEUTICAS QUE COMPRENDEN COMO INGREDIENTES ACTIVOS UN INHIBIDOR DE ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) A UN NIVEL DE DOSIFICACION QUE SE ENCUENTRA NORMALMENTE EFECTIVO COMO ANTI-HIPERTENSIVO Y UN DIURETICO A UN NIVEL DE DOSIFICACION POR DEBAJO DE SU DOSIS EFECTIVA MINIMA, DEMUESTRA UNA MAYOR EFICACIA DE LA QUE SE HUBIERA ESPERADO EN EL RETORNO DE LA PRESION SANGUINEA DE PACIENTES HIPERTENSOS A VALORES DE TENSION NORMAL.
ES93906266T 1992-03-11 1993-03-02 Combinaciones de inhibidores ace y diureticos. Pending ES2083931T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84955492A 1992-03-11 1992-03-11

Publications (1)

Publication Number Publication Date
ES2083931T1 true ES2083931T1 (es) 1996-05-01

Family

ID=25305985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906266T Pending ES2083931T1 (es) 1992-03-11 1993-03-02 Combinaciones de inhibidores ace y diureticos.

Country Status (11)

Country Link
US (1) US5686451A (es)
EP (1) EP0643580A4 (es)
JP (1) JPH07504659A (es)
AU (1) AU686097B2 (es)
CA (1) CA2130577C (es)
DK (1) DK9200258U4 (es)
ES (1) ES2083931T1 (es)
NO (1) NO306931B1 (es)
NZ (1) NZ249773A (es)
WO (1) WO1993017685A1 (es)
ZA (1) ZA931714B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
GB2318057B (en) * 1995-08-02 1999-09-22 Oxford Health Management Ltd Treatment of nocturnal polyuria and medicaments therefor
GB9515826D0 (en) * 1995-08-02 1995-10-04 Oxford Health Management Ltd Treatment of nocturnal polyuria and medicaments therefor
SE9600120D0 (sv) * 1996-01-15 1996-01-15 Astra Ab Novel medical use
FR2771010B1 (fr) * 1997-11-19 2003-08-15 Adir Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
NZ517468A (en) 1999-08-30 2004-02-27 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
WO2001080895A2 (en) * 2000-04-26 2001-11-01 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
US7226474B2 (en) 2000-05-01 2007-06-05 Endovascular Technologies, Inc. Modular graft component junctions
US7666221B2 (en) * 2000-05-01 2010-02-23 Endovascular Technologies, Inc. Lock modular graft component junctions
CA2413201A1 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
JP2005503378A (ja) * 2001-08-06 2005-02-03 ジエノメツド・エル・エル・シー Ａｃｅの過剰に関連する疾患の治療方法及び組成物
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8211166B2 (en) * 2002-02-26 2012-07-03 Endovascular Technologies, Inc. Endovascular grafting device
US7708771B2 (en) * 2002-02-26 2010-05-04 Endovascular Technologies, Inc. Endovascular graft device and methods for attaching components thereof
US7942924B1 (en) 2002-03-04 2011-05-17 Endovascular Technologies, Inc. Staged endovascular graft delivery system
RU2203063C1 (ru) * 2002-03-12 2003-04-27 Нестерук Владимир Викторович Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
CA2530788C (en) * 2003-06-26 2010-02-09 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
EP1734931A2 (en) 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
RU2266751C1 (ru) * 2004-06-04 2005-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Комбинированное гипотензивное средство
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
JP2009533461A (ja) * 2006-04-19 2009-09-17 テバ ファーマシューティカル インダストリーズ リミティド ２−アザ−ビシクロ［３．３．０］−オクタン−３−カルボン酸誘導体の安定な医薬組成物
CA2659814A1 (en) * 2006-07-10 2008-01-17 Teva Pharmaceutical Industries Ltd. Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
RU2618471C2 (ru) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Пероральная фармацевтическая композиция диуретика и ингибитора АПФ в микронизированной форме, лекарственное средство и его применение

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1120400A (en) * 1977-12-27 1982-03-23 Zola P. Horovitz Method of treating hypertension and medicaments therefor
DE3532036A1 (de) * 1985-09-09 1987-03-26 Hoechst Ag Pharmazeutische zubereitung zur behandlung des bluthochdrucks
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
DK0521388T3 (da) * 1991-07-01 1995-09-11 Gergely Gerhard Fremgangsmåde til fremstilling af et farmaceutisk præparat med mindst to forskellige aktivstoffer samt anvendelsen af et sådant præparat

Also Published As

Publication number Publication date
AU686097B2 (en) 1998-02-05
DK9200258U4 (da) 1993-07-23
CA2130577C (en) 2003-09-16
WO1993017685A1 (en) 1993-09-16
EP0643580A1 (en) 1995-03-22
NZ249773A (en) 1996-01-26
NO306931B1 (no) 2000-01-17
ZA931714B (en) 1993-09-30
NO943353L (no) 1994-09-09
NO943353D0 (no) 1994-09-09
JPH07504659A (ja) 1995-05-25
EP0643580A4 (en) 1995-04-19
US5686451A (en) 1997-11-11
CA2130577A1 (en) 1993-09-16
AU3736093A (en) 1993-10-05

Similar Documents

Publication Publication Date Title
ES2083931T1 (es) Combinaciones de inhibidores ace y diureticos.
DE60022525D1 (de) Ramipril zur vorbeugung von kardiovaskulären vorfällen
SE9600072D0 (sv) New oral formulation of two active ingredients II
ES2103952T3 (es) Sistemas terapeuticos transdermicos.
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
ES2153836T3 (es) Composicion enmascaradora del sabor de agentes farmaceuticos amargos.
ES2194050T3 (es) Uso de bisfosfonatos para inhibir la resorcion osea tras la implantacion de una protesis osea.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
ATE333896T1 (de) Vaskularisierungsinhibitoren
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
TNSN01003A1 (fr) Appareil d'administration d'aerosols a comptage de dose dans des propulseurs hydrofluoroalcanes.
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
AR012868A1 (es) COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN PÉPTIDO AGONISTA DE LHRH, UN ANTAGONISTA DE LHRH O UN PÉPTIDO DE GRF Y NICOTINAMIDA.
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
NO983234L (no) Ny medisinsk anvendelse av en ACE-inhibitor for behandling av dyspeptiske symptomer
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
ES2129563T3 (es) Empleo de una combinacion de un inhibidor de la enzima convertidora de angiotensina y un antagonista del calcio para el tratamiento de una proteinuria.
AR027287A1 (es) Gonadotrofina
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
AR034767A1 (es) Combinacion de principios activos para la terapia medicinal de la dependencia a la nicotina.